CTKB logo

Cytek Biosciences Inc. (CTKB)

$5.70

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CTKB

Market cap

$745468612

EPS

-0.64

P/E ratio

--

Price to sales

3.41

Dividend yield

--

Beta

1.150317

Price on CTKB

Previous close

$5.63

Today's open

$5.64

Day's range

$5.47 - $5.74

52 week range

$3.31 - $6.34

Profile about CTKB

CEO

Wenbin Jiang

Employees

682

Headquarters

Fremont, CA

Exchange

Nasdaq Global Select

Shares outstanding

130783967

Issue type

Common Stock

CTKB industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CTKB

Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year

FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug Discovery Innovation of the Year in the 2026 BioTech Breakthrough Awards.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Cytek Biosciences Q3 Earnings Call Highlights

Cytek Biosciences NASDAQ: CTKB reported third-quarter 2026 revenue of $53.2 million, up 2% from a year earlier, as growth in the U.S. and demand for its high-end instruments helped offset weakness in Asia-Pacific.

news source

MarketBeat • Nov 4, 2026

news preview

Cytek Biosciences Reports Third Quarter 2026 Financial Results

FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.01 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences:

news source

GlobeNewsWire • Oct 29, 2026

news preview

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for

Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The company's management will also host a conference call to discuss its results, business developments and outlook beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.

news source

GlobeNewsWire • Oct 21, 2026

news preview

Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.

news source

GlobeNewsWire • Sep 23, 2026

news preview

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Investors need to pay close attention to CTKB stock based on the movements in the options market lately.

news source

Zacks Investment Research • Sep 17, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Cytek Biosciences Inc.

Open an M1 investment account to buy and sell Cytek Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CTKB on M1